Citadel Advisors
BIAFW icon

Citadel Advisors’s bioAffinity Technologies BIAFW Stock Holding History

Citadel Advisors’s Portfolio BIAFW Stock Details BIAFW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55K Sell
19,850
-3,648
-16% -$1.16K ﹤0.01% 12797
2025
Q4 		$7.75K Sell
23,498
-7,086
-23% -$2.53K ﹤0.01% 12448
2025
Q3 		$13.2K Sell
30,584
-1,771
-5% -$252 ﹤0.01% 12548
2025
Q2 		$4.21K Sell
32,355
-3,633
-10% -$636 ﹤0.01% 12243
2025
Q1 		$6.83K Sell
35,988
-14,257
-28% -$5.91K ﹤0.01% 13728
2024
Q4 		$17.1K Buy
50,245
+11,065
+28% +$9.33K ﹤0.01% 13276
2024
Q3 		$45.1K Buy
39,180
+16,959
+76% +$17.6K ﹤0.01% 12032
2024
Q2 		$14K Sell
22,221
-1,959
-8% -$930 ﹤0.01% 12909
2024
Q1 		$18.9K Sell
24,180
-201
-0.8% -$67 ﹤0.01% 13051
2023
Q4 		$2.68K Sell
24,381
-1,337
-5% -$117 ﹤0.01% 13671
2023
Q3 		$2.35K Sell
25,718
-2,823
-10% -$842 ﹤0.01% 13733
2023
Q2 		$10.3K Buy
28,541
+13,304
+87% +$4.12K ﹤0.01% 13214
2023
Q1 		$4.57K Buy
+15,237
New +$5.69K ﹤0.01% 13944

Other funds holding BIAFW

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's BIAFW Position: Q1 2026 in Review

Citadel Advisors reduced its bioAffinity Technologies (BIAFW) stake by 16% in Q1 2026, selling an estimated $1.16K and leaving 19,850 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #12797.

Citadel Advisors first reported a position in BIAFW in Q1 2023 and has held it in 13 quarters since. The position peaked at $45.1K in Q3 2024. 4 funds tracked by Wall St. Rank hold BIAFW as of Q1 2026.

  • Citadel Advisors held 19,850 shares of bioAffinity Technologies worth $6.55K as of Q1 2026.
  • Citadel Advisors sold 3,648 bioAffinity Technologies shares in Q1 2026, an estimated $1.16K.
  • bioAffinity Technologies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12797 holding.
  • Citadel Advisors first reported a position in bioAffinity Technologies in Q1 2023 and has held it in 13 quarters since.
  • Citadel Advisors's bioAffinity Technologies position peaked at $45.1K in Q3 2024.
  • 4 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.